Thus, current treatment approaches for AML patients with activating FLT3 mutations might provide not only feasible but also highly effective targeted therapy combinations that have the potential of remission induction also in younger patients who are eligible for alloHSCT. Here, FLT3 is linked to acute myeloid leukemia.